Skip to content

Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China

Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China: a Multi-center, Prospective Random Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01806454
Enrollment
11000
Registered
2013-03-07
Start date
2013-10-31
Completion date
Unknown
Last updated
2015-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Brief summary

the purpose of this study is to determine whether calcium supplementation is effective to prevent preeclampsia in Sichuang Province of china and which dose is more suitable

Interventions

DRUGcalcium

Sponsors

Sichuan Academy of Medical Sciences
CollaboratorOTHER
Guang'an people's hospital of Sichuan province
CollaboratorOTHER
pengzhou shi fuyou baojianyuan
CollaboratorUNKNOWN
The First People's Hospital of Neijiang
CollaboratorOTHER
Suining Central Hospital
CollaboratorOTHER
Sichuan Provincial Maternal and Child Health Care Hospital
CollaboratorUNKNOWN
Chengdu Women's and Children's Central Hospital
CollaboratorOTHER
West China Second University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Nulliparity;age ≥35 years;Previous pre-eclampsia;Family history of pre-eclampsia;Multiple pregnancy;Time between pregnancies ≥10years;Body mass index ≥25;diastolic pressure ≥ 80 mm Hg before 20 weeks' gestation;Proteinuria ≥+ on more than one occasion or ≥ 300 mg/24 h before 20 weeks' gestation;Underlying medical conditions(Pre-existing hypertension;Pre-existing renal disease;Pre-existing diabetes;Presence of antiphospholipid antibodies;Chronic autoimmune disease);male sex partner's predecessor wife has Previous pre-eclampsia

Exclusion criteria

* first prenatal visit after 16 weeks' gestation;severe anemia;other Underlying medical conditions which need treatment first (such as uncontrolled hyperthyreosis )

Design outcomes

Primary

MeasureTime frame
incidence of pre-eclampsiapostpartum forty-two days

Countries

China

Contacts

Primary Contactpeng chen
cpyxwd007@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026